# Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

> **NCT04334174** · PHASE2 · WITHDRAWN · sponsor: **University of Kansas Medical Center**

## Conditions studied

- T Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT04334174
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05-29
- **Primary completion:** 2022-12-14
- **Final completion:** 2023-02-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** accrual not met
- **Last updated:** 2023-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04334174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04334174, "Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04334174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*